Drugs / 177Lu-B5-IgG4
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT05623891 | Dec 2022 → Dec 2023 | cancer | Affiliated Hospital of Jiangnan University | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 177Lu-B5-IgG4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05623891 ↗ |
| Modality | Monoclonal antibody | “177Lu-labeled anti-ED-B mAbs” NCT05623891 ↗ |
| Route | Intravenous | “Patients will receive a tracer (5 mg, IV) dose of 177Lu (10 mCi) labeled anti-ED-B mAbs(177Lu-B5-IgG4)” NCT05623891 ↗ |